Health · Medical Research · 6 hrs ago
Trastuzumab Rezetecan Cuts Progression Risk in HER2-Low Breast Cancer Trial
A Chinese phase III trial tested trastuzumab rezetecan in patients with HER2-low metastatic breast cancer.
The drug is an investigational antibody-drug conjugate, meaning it is still being studied.
The trial found that it significantly reduced the risk of disease progression or death among the patients studied.
The result concerns people with HER2-low metastatic breast cancer, a group with advanced disease.
The trial was conducted in China.
The available information does not say what happens next in the drug’s development.
An investigational drug called trastuzumab rezetecan significantly reduced the risk of disease progression or death in patients with HER2-low metastatic breast cancer.
The finding came from a Chinese phase III trial.
Trastuzumab rezetecan is an antibody-drug conjugate.
The article did not report the size of the risk reduction.
- Who
- Patients with HER2-low metastatic breast cancer.
- What
- An investigational drug significantly reduced the risk of disease progression or death in a phase III trial.
- When
- Not stated
- Where
- A Chinese phase III trial; the location was not stated.
- Why
- Not stated
This story does not have two clearly opposing sides.
This story does not have a timeline yet.
- Drug
- Trastuzumab rezetecan
- Drug type
- Investigational antibody-drug conjugate
- Trial phase
- Phase III
- Patient group
- HER2-low metastatic breast cancer